Compare Rent the Runway Inc (RENT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rent the Runway Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Rent the Runway Inc trades at $1.77 (market cap $61.75M), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2065.6× Rent the Runway Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rent the Runway Inc for 56 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| RENT | VRTX | |
|---|---|---|
Market Cap | $61.75M | $127.55B |
Volume | 193,323 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $9.39 | $557.96 |
52-Week Low | $1.55 | $407.37 |
Typical Hold Time | 56 Days | 120 Days |
Enterprise Value | $228.75M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rent the Runway (RENT) trades at $1.83, up 8.93% on the day, showing volatile earnings with recent quarterly beats but negative annual net income. The stock has a bullish technical signal despite mixed indicators, with valuation ratios appearing attractive (P/E 0.14, P/S 0.13). Revenue growth is improving, reaching $306.20M in 2025, with profitability metrics showing margin expansion from -104.19% in 2022 to -22.83% in 2025.
The outlook remains challenging with significant debt burden (debt-to-asset ratio 139.62%) and negative shareholder equity, though 2026 projections show potential profitability. Analyst consensus leans Hold (57.89%) with no Sell ratings, suggesting cautious optimism. Key risks include ongoing legal investigations and execution challenges in achieving sustained profitability.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, with a bearish technical signal despite strong fundamentals. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b data for inaxaplin in kidney disease shows pipeline expansion potential. Revenue grew to $12.0B in 2025 with $3.95B net income, recovering from 2024's loss.
Analyst consensus remains strongly bullish with 84% buy ratings and $573.50 price target, representing 14% upside. Key risks include pipeline execution and competitive pressures. The stock offers growth potential through gene therapy expansion but faces volatility from clinical trial outcomes and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
